These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1350 related articles for article (PubMed ID: 30166073)

  • 1. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
    Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
    Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
    Ge Z; Kan J; Gao X; Raza A; Zhang JJ; Mohydin BS; Gao F; Shao Y; Wang Y; Zeng H; Li F; Khan HS; Mengal N; Cong H; Wang M; Chen L; Wei Y; Chen F; Stone GW; Chen SL;
    Lancet; 2024 May; 403(10439):1866-1878. PubMed ID: 38599220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
    Vranckx P; Valgimigli M; Windecker S; Steg PG; Hamm C; Jüni P; Garcia-Garcia HM; van Es GA; Serruys PW
    EuroIntervention; 2016 Nov; 12(10):1239-1245. PubMed ID: 26606735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
    Vranckx P; Valgimigli M; Odutayo A; Serruys PW; Hamm C; Steg PG; Heg D; Mc Fadden EP; Onuma Y; Benit E; Janssens L; Diletti R; Ferrario M; Huber K; Räber L; Windecker S; Jüni P;
    J Am Heart Assoc; 2021 Sep; 10(18):e015560. PubMed ID: 34533034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
    Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW;
    JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
    Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial.
    Kogame N; Chichareon P; De Wilder K; Takahashi K; Modolo R; Chang CC; Tomaniak M; Komiyama H; Chieffo A; Colombo A; Garg S; Louvard Y; Jüni P; G Steg P; Hamm C; Vranckx P; Valgimigli M; Windecker S; Stoll HP; Onuma Y; Janssens L; Serruys PW
    Catheter Cardiovasc Interv; 2020 Jul; 96(1):100-111. PubMed ID: 31410968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
    Jin C; Kim MH; Bang J; Serebruany V
    Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial.
    Hong SJ; Lee SJ; Suh Y; Yun KH; Kang TS; Shin S; Kwon SW; Lee JW; Cho DK; Park JK; Bae JW; Kang WC; Kim S; Lee YJ; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK;
    Circulation; 2024 Feb; 149(8):562-573. PubMed ID: 37878786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
    Kim CJ; Park MW; Kim MC; Choo EH; Hwang BH; Lee KY; Choi YS; Kim HY; Yoo KD; Jeon DS; Shin ES; Jeong YH; Seung KB; Jeong MH; Yim HW; Ahn Y; Chang K;
    Lancet; 2021 Oct; 398(10308):1305-1316. PubMed ID: 34627490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
    Koo BK; Kang J; Park KW; Rhee TM; Yang HM; Won KB; Rha SW; Bae JW; Lee NH; Hur SH; Yoon J; Park TH; Kim BS; Lim SW; Cho YH; Jeon DW; Kim SH; Han JK; Shin ES; Kim HS;
    Lancet; 2021 Jun; 397(10293):2487-2496. PubMed ID: 34010616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
    Serruys PW; Takahashi K; Chichareon P; Kogame N; Tomaniak M; Modolo R; Chang CC; Komiyama H; Soliman O; Wykrzykowska JJ; de Winter RJ; Ferrario M; Dominici M; Buszman P; Bolognese L; Tumscitz C; Benit E; Stoll HP; Hamm C; Steg PG; Onuma Y; Jüni P; Windecker S; Vranckx P; Colombo A; Valgimigli M
    Eur Heart J; 2019 Aug; 40(31):2595-2604. PubMed ID: 31397487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
    Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
    Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial.
    Ono M; Chichareon P; Tomaniak M; Kawashima H; Takahashi K; Kogame N; Modolo R; Hara H; Gao C; Wang R; Walsh S; Suryapranata H; da Silva PC; Cotton J; Koning R; Akin I; Rensing BJWM; Garg S; Wykrzykowska JJ; Piek JJ; Jüni P; Hamm C; Steg PG; Valgimigli M; Windecker S; Storey RF; Onuma Y; Vranckx P; Serruys PW
    Clin Res Cardiol; 2020 Sep; 109(9):1125-1139. PubMed ID: 32006156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects.
    Traby L; Kollars M; Kaider A; Eichinger S; Wolzt M; Kyrle PA
    J Thromb Haemost; 2016 Feb; 14(2):273-81. PubMed ID: 26663880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Parker WA; Storey RF
    Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial.
    Li Y; Li J; Wang B; Jing Q; Zeng Y; Hou A; Wang Z; Liu A; Zhang J; Zhang Y; Zhang P; Jiang D; Liu B; Fan J; Zhang J; Li L; Su G; Yang M; Jiang W; Qu P; Zeng H; Li L; Qiu M; Ru L; Chen S; Zhou Y; Qiao S; Stone GW; Angiolillo DJ; Han Y;
    JAMA Cardiol; 2024 Jun; 9(6):523-531. PubMed ID: 38630489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.